New drug combo aims to boost bladder cancer remission before surgery

NCT ID NCT06059547

Ongoing Disease control Sponsor: CatalYm GmbH Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether adding visugromab to the immunotherapy nivolumab helps shrink muscle-invasive bladder cancer before surgery. The study includes 31 patients who cannot take or refuse standard cisplatin chemotherapy. The main goal is to see how many patients have no cancer left in their bladder after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: visugromab (CTL-002) and nivolumab
What this could lead to: If successful, this combination could offer a new treatment option for muscle-invasive bladder cancer patients who cannot receive standard chemotherapy, potentially increasing the chance of a complete response before surgery.
What could go wrong: This is a small, early-phase (Phase 2) study with only 31 participants. The results may not apply to all patients, and the combination may cause side effects or not improve outcomes compared to existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT SOLID TUMOR BLADDER CANCER

Contacts and locations

Locations

A.O.U. Città della Salute e della Scienza di Torino

Torino, 10126, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, 20133, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Oncologia Medica

Roma, 00168, Italy
IRCCS Ospedale San Raffaele Hospital Vita-Salute San Raffaele University

Milan, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.